QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening

Friday, October 20, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Evaluation of clinical variant interpretation platform presented by Counsyl at ASHG 2017

ORLANDO, GERMANTOWN, Maryland, and HILDEN, Germany, October

19, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company. In an evaluation, Counsyl - an early QCI adopter - found that it reduced the time required to search for literature references to interpret and score variants by 75 percent while maintaining accuracy. As a result, Counsyl has implemented QCI as an integral part of its literature search process to increase productivity and scalability. Results of the evaluation are presented today in a poster at the American Society of Human Genetics (ASHG).

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en

Contacts: Investor Relations John Gilardi E-Mail: [email protected] +49-2103-29-11711 Public Relations Dr. Thomas Theuringer E-Mail: [email protected] +49-2103-29-11826

SOURCE QIAGEN



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store